Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (SPARROW)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01446211|
Recruitment Status : Terminated (Change of design consideration)
First Posted : October 5, 2011
Last Update Posted : May 29, 2015
|Condition or disease||Intervention/treatment||Phase|
|Wegeners Granulomatosis||Drug: Gusperimus + glucocorticoids Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||January 2015|
Experimental: Test group - gusperimus
Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
Drug: Gusperimus + glucocorticoids
Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
Active Comparator: Control group
The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.
The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .
Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
- Response rate [ Time Frame: 52 weeks ]
The primary efficacy variable is the rate of patients showing a response, with the level of disease activity Birmingham Vasculitis Activity Score (BVAS) ≤ 2, within 24 weeks of trial entry, which is maintained without relapse until the end of the trial (Week 52).
The primary efficacy endpoint includes:
i) Remission - defined as the complete absence of active clinical disease, i.e. a BVAS score of 0, for at least two months on a stable prednisone dose of ≤ 10 mg/day.
ii) Low activity Disease State - persistence of up to two minor BVAS items (BVAS ≤ 2).
- Time to response [ Time Frame: From the date of study entry until the first occasion that BVAS is ≤ 2, assessed up to 52 weeks ]Time to response (response is defined as the time from study entry to the first occasion that BVAS is ≤ 2, and there has been adherence to the steroid reduction protocol)
- Response duration [ Time Frame: From the date of response with BVAS≤2 until relapse, assessed up to 48 weeks ]Response duration defined as time from response with BVAS≤2 to relapse (relapse is defined as the return or first occurrence of one major and/or three minor BVAS items)
- Frequency of severe relapses [ Time Frame: Up to 52 weeks ]Frequency of severe relapses (defined as at least one major BVAS item)
- Vasculitis Damage Index (VDI) score change [ Time Frame: 12 months ]VDI score change from baseline to month 12
- Glomerular Filtration Rate (eGFR) change [ Time Frame: 12 months ]eGFR change from baseline to month 12 in all patients and in a subgroup defined as having a baseline eGFR ≤ 60mL/min (i.e. renal impairment at baseline)
- Frequency of Adverse Events (AEs) and Serious Adverse Event (SAEs) [ Time Frame: Up to 52 weeks ]Frequency of AEs and SAEs. (Total number of AEs per group according to AE category) (Percentage of patients in each group with a severe AE)
- Frequency of severe infection [ Time Frame: Up to 52 weeks ]Frequency of severe infection (a severe infection is defined as an infection that requires intravenous antibiotics or hospitalisation).(Percentage of patients in each group with a severe infection)
- Pharmacokinetic parameters at selected sites [ Time Frame: 1st day of gusperimus cycles 1, 6 or 7, 12 or 13 ]Pharmacokinetic parameters Area Under the plasmaconcentration - time Curve (AUC), Maximum concentration reached in plasma (Cmax), Time to maximum concentration reached in plasma (Tmax) and Elimination half life in plasma (T½) calculated from the measured plasma samples collected at regular time intervals after administration of gusperimus on the first day of three treatment cycles
- Short-Form-36 (SF-36) [ Time Frame: 6 months ]Pooled physical and mental SF-36 domains change from baseline to month 6
- Short-Form-36 (SF-36) [ Time Frame: 12 months ]Pooled physical and mental SF-36 domains change from baseline to month 12
- Total corticosteroid exposure [ Time Frame: Up to 52 weeks ]The total corticosteroid exposure
- Questionnaire EQ-5D [ Time Frame: 12 months ]Change in EQ-5D between baseline and month 12
- Frequency of non-severe relapses [ Time Frame: Up to 52 weeks ]Frequency of non-severe relapses (defined as at least 3 minor BVAS items with no major BVAS items).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01446211
|Všeobecná fakultní nemocnice v Praze|
|Praha, Czech Republic, 128 08|
|Principal Investigator:||David Jayne, MD||Addenbrookes Hospital, Cambridge, United Kingdom|